Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Prostate cancer, new treatment advances — Immunotherapy
Journal Information
Vol. 44. Issue 7.
Pages 458-468 (September 2020)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 44. Issue 7.
Pages 458-468 (September 2020)
Review article
DOI: 10.1016/j.acuroe.2020.01.010
Prostate cancer, new treatment advances — Immunotherapy
Cáncer de próstata, nuevas opciones de tratamiento: inmunoterapia
Visits
...
D. Silvaa, P. Abreu-Mendesb,c, C. Mouratod, D. Martinsd,e, R. Cruza, F. Mendesd,f,g,h,
Corresponding author
fjmendes@estescoimbra.pt

Corresponding author.
a Politécnico de Coimbra, ESTeSC, DFarm, Coimbra, Portugal
b Serviço de Urologia, Centro Hospital Universitário de São João, Porto, Portugal
c Faculty of Medicine, University of Porto, Porto, Portugal
d Politécnico de Coimbra, ESTeSC, DCBL, Coimbra, Portugal
e I3S, Instituto de Investigação e Inovação em Saúde, University of PortoCNC.IBILI Consortium/Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Porto, Portugal
f CNC.IBILI Consortium/Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
g Biophysics Institute, Coimbra Institute for Clinical and Biomedical Research (iCBR), Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
h European Association for Professions in Biomedical Sciences
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (3)
Table 1. Bibliographic reviews inserted in this review.
Table 2. Clinical Trials inserted in this review.
Table 3. Summary of selected ongoing/completed trials combining immunotherapy with other agents.
Show moreShow less
Abstract

Prostate cancer (PCa) is the fourth most common cancer in the world and treatment is currently based on surgical removal and/or radiotherapy and/or hormone therapy. In the last few years’ immunotherapy has become an important cancer treatment option. While the principles of immunotherapy evolved, only sipuleucel-T was approved by the Food and Drug Administration (FDA) which lead to further studies with other agents, starting a new era in immuno-oncology. A number of vaccines are under clinical investigation as well as checkpoint inhibitors. Despite the current enthusiasm, it is unlikely that any of the approaches alone can dramatically change PCa outcomes, but strategies combination is more promising and provide a reason for optimism. The goal of immunotherapy in PCa does not have to be the complete eradication of advanced disease, but rather the return to an immunologic equilibrium with an indolent disease state. With such concerted efforts, the future of immunotherapy in PCa looks brighter than ever, with many clinical trial results being published soon.

Keywords:
Prostatic neoplasms
Therapeutics
Immunotherapy
Metastatic
Resumen

El cáncer de próstata (CaP) es el cuarto cáncer más común en el mundo, y el tratamiento se basa actualmente en la extirpación quirúrgica y/o la radioterapia y/o la terapia hormonal. En los últimos años la inmunoterapia se ha convertido en una importante opción para el tratamiento del cáncer, y aunque los principios de la inmunoterapia evolucionaron durante varios años, la Food and Drug Administration (FDA) estadounidense solo aprobó el sipuleucel-T, lo que condujo a estudios adicionales con otros agentes, comenzando una nueva era en inmuno-oncología. Se están investigando varias vacunas, así como inhibidores de puntos de control. A pesar del entusiasmo actual, es poco probable que cualquiera de los inmunoterapéuticos por sí solo pueda cambiar drásticamente los resultados del CaP, pero las estrategias combinadas son más prometedoras y proporcionan una razón para el optimismo. El objetivo de la inmunoterapia con CaP no tiene que ser la erradicación completa de la enfermedad avanzada, sino más bien el retorno a un equilibrio inmunológico con un estado de enfermedad indolente. Con esfuerzos tan concertados, el futuro de la inmunoterapia en CaP parece más brillante que nunca, y los resultados de muchos ensayos clínicos se publicarán pronto.

Palabras clave:
Neoplasias prostáticas
Medicamentos
Inmunoterapia
Metastásico

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.